| Year |
Citation |
Score |
| 2022 |
Brand TM, Hartmann S, Bhola NE, Li H, Zeng Y, O'Keefe RA, Ranall MV, Bandyopadhyay S, Soucheray M, Krogan NJ, Kemp C, Duvvuri U, LaVallee T, Johnson DE, Ozbun MA, et al. Correction: Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer. Cancer Research. 82: 3187. PMID 36052496 DOI: 10.1158/0008-5472.CAN-22-1308 |
0.527 |
|
| 2022 |
Brand TM, Hartmann S, Bhola NE, Li H, Zeng Y, O'Keefe RA, Ranall MV, Bandyopadhyay S, Soucheray M, Krogan NJ, Kemp C, Duvvuri U, LaVallee T, Johnson DE, Ozbun MA, et al. Editor's Note: Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer. Cancer Research. 82: 3188. PMID 36052495 DOI: 10.1158/0008-5472.CAN-22-1307 |
0.524 |
|
| 2021 |
Swaney DL, Ramms DJ, Wang Z, Park J, Goto Y, Soucheray M, Bhola N, Kim K, Zheng F, Zeng Y, McGregor M, Herrington KA, O'Keefe R, Jin N, VanLandingham NK, et al. A protein network map of head and neck cancer reveals PIK3CA mutant drug sensitivity. Science (New York, N.Y.). 374: eabf2911. PMID 34591642 DOI: 10.1126/science.abf2911 |
0.425 |
|
| 2021 |
Bouhaddou M, Lee RH, Li H, Bhola NE, O'Keefe RA, Naser M, Zhu TR, Nwachuku K, Duvvuri U, Olshen AB, Roy R, Hechmer A, Bolen J, Keysar SB, Jimeno A, et al. Caveolin-1 and Sox-2 are predictive biomarkers of cetuximab response in head and neck cancer. Jci Insight. PMID 34546978 DOI: 10.1172/jci.insight.151982 |
0.538 |
|
| 2021 |
Bhola NE, Njatcha C, Hu L, Lee ED, Shiah JV, Kim MO, Johnson DE, Grandis JR. PD-L1 is upregulated via BRD2 in head and neck squamous cell carcinoma models of acquired cetuximab resistance. Head & Neck. PMID 34346116 DOI: 10.1002/hed.26827 |
0.489 |
|
| 2021 |
Brand TM, Hartmann S, Bhola NE, Peyser ND, Li H, Zeng Y, Wechsler EI, Ranall MV, Bandyopadhyay S, Duvvuri U, LaVallee TM, Jordan RCK, Johnson DE, Grandis JR. Correction: Human Papillomavirus Regulates HER3 Expression in Head and Neck Cancer: Implications for Targeted HER3 Therapy in HPV Patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 27: 4129. PMID 34261774 DOI: 10.1158/1078-0432.CCR-21-2141 |
0.516 |
|
| 2020 |
O'Keefe RA, Bhola NE, Lee DS, Johnson DE, Grandis JR. Interleukin 6 is increased in preclinical HNSCC models of acquired cetuximab resistance, but is not required for maintenance of resistance. Plos One. 15: e0227261. PMID 31914141 DOI: 10.1371/Journal.Pone.0227261 |
0.488 |
|
| 2020 |
Bhola N, Givmanesh A, Wagle M, Garcia C, Vaidya K, Cleary L, Pei Z, Lackner M, Mounir Z. Abstract 631: Mat2A Inhibitors decrease growth, increase senescence and p53 stability in MTAP-deleted cancer cells Cancer Research. 80: 631-631. DOI: 10.1158/1538-7445.Am2020-631 |
0.429 |
|
| 2019 |
Leonard BC, Lee ED, Bhola NE, Li H, Sogaard KK, Bakkenist CJ, Grandis JR, Johnson DE. ATR inhibition sensitizes HPV and HPV head and neck squamous cell carcinoma to cisplatin. Oral Oncology. 95: 35-42. PMID 31345392 DOI: 10.1016/J.Oraloncology.2019.05.028 |
0.501 |
|
| 2019 |
Chakrabarty A, Surendran S, Bhola NE, Mishra VS, Wani TH, Baghel KS, Arteaga CL, Garg R, Chowdhury G. The H1047R PIK3CA oncogene induces a senescence-like state, pleiotropy and acute HSP90 dependency in HER2+ mammary epithelial cells. Carcinogenesis. PMID 31219154 DOI: 10.1093/Carcin/Bgz118 |
0.304 |
|
| 2019 |
Bhola NE, Jansen VM, Koch JP, Li H, Formisano L, Williams JA, Grandis JR, Arteaga CL. Correction: Treatment of Triple-Negative Breast Cancer with TORC1/2 Inhibitors Sustains a Drug-Resistant and Notch-Dependent Cancer Stem Cell Population. Cancer Research. 79: 875. PMID 30770370 DOI: 10.1158/0008-5472.CAN-18-4087 |
0.456 |
|
| 2019 |
Hedberg ML, Peyser ND, Bauman JE, Gooding WE, Li H, Bhola NE, Zhu TR, Zeng Y, Brand TM, Kim MO, Jordan RCK, VandenBerg S, Olivas V, Bivona TG, Chiosea SI, et al. Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for -altered head and neck cancer. The Journal of Experimental Medicine. PMID 30683736 DOI: 10.1084/Jem.20181936 |
0.437 |
|
| 2018 |
Leonard B, Brand TM, O'Keefe RA, Lee E, Zang Y, Kemmer JD, Li H, Grandis JR, Bhola NE. BET inhibition overcomes receptor tyrosine kinase-mediated cetuximab resistance in HNSCC. Cancer Research. PMID 29792310 DOI: 10.1158/0008-5472.Can-18-0459 |
0.579 |
|
| 2018 |
Brand TM, Hartmann S, Bhola NE, Li H, Zang Y, O'Keefe RA, Ranall MV, Bandyopadhyay S, Soucheray M, Krogan NJ, Kemp C, Duvvuri U, LaVallee T, Johnson DE, Ozbun MA, et al. Crosstalk signaling between HER3 and HPV16 E6 and E7 mediates resistance to PI3K inhibitors in head and neck cancer. Cancer Research. PMID 29440171 DOI: 10.1158/0008-5472.Can-17-1672 |
0.567 |
|
| 2017 |
Sun C, Fang Y, Yin J, Chen J, Ju Z, Zhang D, Chen X, Vellano CP, Jeong KJ, Ng PK, Eterovic AKB, Bhola NH, Lu Y, Westin SN, Grandis JR, et al. Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers. Science Translational Medicine. 9. PMID 28566428 DOI: 10.1126/Scitranslmed.Aal5148 |
0.472 |
|
| 2017 |
Surendran S, Bhola N, Arteaga C, Chakraborty K, Chakrabarty A. Abstract P1-08-10: Introduction of H1047R oncogenic mutation of PI3K p110alpha subunit in HER2-overexpressing mammary epithelial cells confers a "stem-like" phenotype and acute sensitivity to HSP90 inhibition Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P1-08-10 |
0.331 |
|
| 2017 |
O'Keefe RA, Bhola N, Brand TM, Zeng Y, Johnson DE, Grandis JR. Abstract 4108: Targeting IL-6 signaling overcomes cetuximab resistance in head and neck squamous cell carcinoma Cancer Research. 77: 4108-4108. DOI: 10.1158/1538-7445.Am2017-4108 |
0.545 |
|
| 2016 |
Grandis JR, Brand TM, Hartmann S, Bhola NE, Peyser ND, Li H, Zeng Y, Isaacson Wechsler E, Ranall MV, Bandyopadhyay S, Duvvuri U, LaVallee TM, Jordan RC, Johnson DE. Human papillomavirus regulates HER3 expression in head and neck cancer: implications for targeted HER3 therapy in HPV(+) patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27986750 DOI: 10.1158/1078-0432.Ccr-16-2203 |
0.492 |
|
| 2016 |
Bhola NE, Johnson DE, Grandis JR. A sensible approach to targeting STAT3-mediated transcription. Annals of Translational Medicine. 4: S57. PMID 27868025 DOI: 10.21037/Atm.2016.10.51 |
0.482 |
|
| 2016 |
Hartmann S, Bhola NE, Grandis JR. HGF/Met Signaling in Head and Neck Cancer: Impact on the Tumor Microenvironment. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27370607 DOI: 10.1158/1078-0432.Ccr-16-0951 |
0.597 |
|
| 2016 |
Formisano L, Young C, Bhola N, Bulen B, Estrada V, Wagle N, Allen EV, Brewer MR, Jansen V, Guerrero A, Giltnane J, Strcker T, Arteaga C. Abstract S3-03: Nuclear FGFR1 interaction with estrogen receptor (ER) α is associated with resistance to endocrine therapy in ER+/FGFR1-amplified breast cancer Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-S3-03 |
0.398 |
|
| 2016 |
Jansen V, Bhola N, Bauer J, Formisano L, Moore P, Koch J, Arteaga C. Abstract PD2-06: Inhibition of 3-phosphoinositide dependent protein kinase 1 (PDK1) synergizes with CDK4/6 inhibitors against ER-positive breast cancer Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-Pd2-06 |
0.454 |
|
| 2016 |
Brand TM, Hartmann S, Bhola N, Peyser ND, Li H, Zeng Y, Randall MV, Bandyopadhyay S, Grandis JR. Abstract 1205: HER3 is a functional molecular target in HPV-associated head and neck cancer Cancer Research. 76: 1205-1205. DOI: 10.1158/1538-7445.Am2016-1205 |
0.575 |
|
| 2015 |
Bhola NE, Jansen VM, Koch JP, Li H, Formisano L, Williams JA, Grandis JR, Arteaga CL. Treatment of Triple Negative Breast Cancer With TORC1/2 Inhibitors Sustains a Drug-resistant and Notch-dependent Cancer Stem Cell Population. Cancer Research. PMID 26676751 DOI: 10.1158/0008-5472.Can-15-1640-T |
0.541 |
|
| 2015 |
Hover LD, Young CD, Bhola NE, Wilson AJ, Khabele D, Hong CC, Moses HL, Owens P. Small molecule inhibitor of the bone morphogenetic protein pathway DMH1 reduces ovarian cancer cell growth. Cancer Letters. PMID 26235139 DOI: 10.1016/J.Canlet.2015.07.032 |
0.348 |
|
| 2015 |
Young CD, Zimmerman LJ, Hoshino D, Formisano L, Hanker AB, Gatza ML, Morrison MM, Moore PD, Whitwell CA, Dave B, Stricker T, Bhola NE, Silva GO, Patel P, Brantley-Sieders DM, et al. Activating PIK3CA Mutations Induce an Epidermal Growth Factor Receptor (EGFR)/Extracellular Signal-regulated Kinase (ERK) Paracrine Signaling Axis in Basal-like Breast Cancer. Molecular & Cellular Proteomics : McP. 14: 1959-76. PMID 25953087 DOI: 10.1074/Mcp.M115.049783 |
0.365 |
|
| 2015 |
Bhola NE, Jansen VM, Bafna S, Giltnane JM, Balko JM, Estrada MV, Meszoely I, Mayer I, Abramson V, Ye F, Sanders M, Dugger TC, Allen EV, Arteaga CL. Kinome-wide functional screen identifies role of PLK1 in hormone-independent, ER-positive breast cancer. Cancer Research. 75: 405-14. PMID 25480943 DOI: 10.1158/0008-5472.Can-14-2475 |
0.409 |
|
| 2013 |
Balko JM, Schwarz LJ, Bhola NE, Kurupi R, Owens P, Miller TW, Gómez H, Cook RS, Arteaga CL. Activation of MAPK pathways due to DUSP4 loss promotes cancer stem cell-like phenotypes in basal-like breast cancer. Cancer Research. 73: 6346-58. PMID 23966295 DOI: 10.1158/0008-5472.Can-13-1385 |
0.304 |
|
| 2013 |
Chakrabarty A, Bhola NE, Sutton C, Ghosh R, Kuba MG, Dave B, Chang JC, Arteaga CL. Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors. Cancer Research. 73: 1190-200. PMID 23204226 DOI: 10.1158/0008-5472.Can-12-2440 |
0.348 |
|
| 2013 |
Bhola N, Arteaga C. Abstract PD5-1: The type II TGFb receptor neutralizing antibody, TR1, abrogates the tumor-initiating cell (TIC) population in triple negative breast cancer (TNBC) via inhibition of SMAD and non-SMAD pathways Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-Pd5-1 |
0.515 |
|
| 2012 |
Bhola NE, Freilino ML, Joyce SC, Sen M, Thomas SM, Sahu A, Cassell A, Chen CS, Grandis JR. Antitumor mechanisms of targeting the PDK1 pathway in head and neck cancer. Molecular Cancer Therapeutics. 11: 1236-46. PMID 22491800 DOI: 10.1158/1535-7163.Mct-11-0936 |
0.631 |
|
| 2011 |
Bhola NE, Thomas SM, Freilino M, Joyce S, Sahu A, Maxwell J, Argiris A, Seethala R, Grandis JR. Targeting GPCR-mediated p70S6K activity may improve head and neck cancer response to cetuximab. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 4996-5004. PMID 21653688 DOI: 10.1158/1078-0432.Ccr-10-3406 |
0.627 |
|
| 2011 |
Bhola N, Arteaga C. PD08-04: Inhibition of the TGFb/TGFbR2 Pathway Prevents Enrichment of Drug-Resistant Breast Cancer Stem Cells by Anti-Cancer Chemotherapy. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-Pd08-04 |
0.434 |
|
| 2011 |
Balko J, Cook R, Kuba M, Miller T, Bhola N, Sanders M, Meszoely I, Dowsett M, Gomez H, Arteaga C. PD08-03: Inhibition of MEK/ERK- and JNK-Dependent Expression of Interleukin-6 and Interleukin-8 Targets Basal-Like Breast Cancer Stem Cells. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-Pd08-03 |
0.386 |
|
| 2010 |
Yang W, Cai Q, Lui VW, Everley PA, Kim J, Bhola N, Quesnelle KM, Zetter BR, Steen H, Freeman MR, Grandis JR. Quantitative proteomics analysis reveals molecular networks regulated by epidermal growth factor receptor level in head and neck cancer. Journal of Proteome Research. 9: 3073-82. PMID 20426488 DOI: 10.1021/Pr901211J |
0.724 |
|
| 2010 |
Leeman-Neill RJ, Cai Q, Joyce SC, Thomas SM, Bhola NE, Neill DB, Arbiser JL, Grandis JR. Honokiol inhibits epidermal growth factor receptor signaling and enhances the antitumor effects of epidermal growth factor receptor inhibitors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 2571-9. PMID 20388852 DOI: 10.1158/1078-0432.Ccr-10-0333 |
0.719 |
|
| 2009 |
Qi Y, Dhiman HK, Bhola N, Budyak I, Kar S, Man D, Dutta A, Tirupula K, Carr BI, Grandis J, Bar-Joseph Z, Klein-Seetharaman J. Systematic prediction of human membrane receptor interactions. Proteomics. 9: 5243-55. PMID 19798668 DOI: 10.1002/Pmic.200900259 |
0.47 |
|
| 2008 |
Zhang W, Bhola N, Kalyankrishna S, Gooding W, Hunt J, Seethala R, Grandis JR, Siegfried JM. Kinin b2 receptor mediates induction of cyclooxygenase-2 and is overexpressed in head and neck squamous cell carcinomas. Molecular Cancer Research : McR. 6: 1946-56. PMID 19074839 DOI: 10.1158/1541-7786.Mcr-07-2197 |
0.643 |
|
| 2008 |
Bhola NE, Grandis JR. Crosstalk between G-protein-coupled receptors and epidermal growth factor receptor in cancer. Frontiers in Bioscience : a Journal and Virtual Library. 13: 1857-65. PMID 17981673 |
0.593 |
|
| 2007 |
Zhang Q, Bhola NE, Lui VW, Siwak DR, Thomas SM, Gubish CT, Siegfried JM, Mills GB, Shin D, Grandis JR. Antitumor mechanisms of combined gastrin-releasing peptide receptor and epidermal growth factor receptor targeting in head and neck cancer. Molecular Cancer Therapeutics. 6: 1414-24. PMID 17431120 DOI: 10.1158/1535-7163.Mct-06-0678 |
0.636 |
|
| 2006 |
Thomas SM, Bhola NE, Zhang Q, Contrucci SC, Wentzel AL, Freilino ML, Gooding WE, Siegfried JM, Chan DC, Grandis JR. Cross-talk between G protein-coupled receptor and epidermal growth factor receptor signaling pathways contributes to growth and invasion of head and neck squamous cell carcinoma. Cancer Research. 66: 11831-9. PMID 17178880 DOI: 10.1158/0008-5472.Can-06-2876 |
0.62 |
|
| Show low-probability matches. |